134 related articles for article (PubMed ID: 37160625)
1. The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
Wang L; Huang S; Zhang P; Li H; Li Z; Xue L; Wang Z; Chen Q; Fu D; Luo Q; Li H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8945-8949. PubMed ID: 37160625
[TBL] [Abstract][Full Text] [Related]
2. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
3. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.
Zhang J; Li M; Chen Z; OuYang J; Ling Z
J Healthc Eng; 2021; 2021():2360717. PubMed ID: 34888022
[TBL] [Abstract][Full Text] [Related]
5. Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Wang T; Niu X; Zhong B
Jpn J Clin Oncol; 2022 May; 52(6):642-649. PubMed ID: 35348732
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor.
Shao LJ; Wang HJ; Wang JR; Yuan XF; Sha Q
Pak J Med Sci; 2022; 38(5):1243-1249. PubMed ID: 35799745
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.
Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z
Oncology; 2024; 102(4):337-342. PubMed ID: 37647883
[TBL] [Abstract][Full Text] [Related]
8. Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.
Kageyama S; Maeda K; Kubota S; Yoshida T; Osafune T; Arai Y; Soga H; Nishikawa Z; Sakano Y; Takimoto K; Kim CJ; Chano T; Kawauchi A
In Vivo; 2021; 35(2):1141-1145. PubMed ID: 33622912
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
10. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
11. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
Xu S; Tan S; Wu T; Gu J; Xu L; Che X
Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
[TBL] [Abstract][Full Text] [Related]
12. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Wang TW; Yuan H; Diao WL; Yang R; Zhao XZ; Guo HQ
BMC Urol; 2019 Oct; 19(1):90. PubMed ID: 31615492
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M
Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462
[TBL] [Abstract][Full Text] [Related]
15. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Pareek T; Parmar K; Sharma AP; Kumar S
Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis.
Cheng W; Zhou Y; Chu X; Huang S; Zheng X; Zheng H
Actas Urol Esp (Engl Ed); 2023 Mar; 47(2):92-98. PubMed ID: 36586485
[TBL] [Abstract][Full Text] [Related]
20. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]